Ponatinib

Red

Brand Name(s):Iclusig

Indication:Chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia

Rationale:1,2,3

Considered:May-13

Review Date:Oct-23

Comments:
Drug Safety Update
Ponatinib (Iclusig): reports of posterior reversible encephalopathy syndrome
Oct 18
…………………………
Drug Safety Update
Risk of vascular occlusive events—updated advice on possible dose reduction
Apr-22
…………………………
Drug Safety Update
Patients should be tested for hepatitis B virus before starting treatment with BCR-ABL tyrosine kinase inhibitors.
May2016
…………………………
MHRA Drug Safety Update – risk of vascular occlusive events,
November 2014